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ABSTRACT: Uterus Transplantation is an experimental vascular composite allograft designed to provide women 5 
with absolute uterine factor infertility with the opportunity to gestate and give birth to their future offspring. The 6 
number of UTx procedures performed worldwide now stand at ≥ 70 and as the number of cases performed increases 7 
so too does the volume of the potential data that may be gathered to inform the development, practice, and regulation 8 
of UTx. Given the value of this data, and the challenges associated with keeping track of cases and outcomes where 9 
data remains unpublished and/or scattered, scientists and academics conducting research into UTx have increasingly 10 
called for the swift creation, implementation, and management of an international registry for Uterus Transplantation 11 
(IRUTx). This paper explores and provides practical guidance regarding the potential benefits the IRUTx may provide 12 
to stakeholders, as well as the legal and ethical challenges that its creation may pose in terms of dataset design,  consent, 13 
privacy, researcher compliance, and governance.  14 
 15 
 16 
1. Introduction 17 
 18 
Uterus Transplantation (UTx) is an experimental vascular composite allograft (VCA) which is designed to provide 19 
women with absolute uterine factor infertility (AUFI) with the opportunity to gestate and give birth to their future 20 
offspring. Research into the procedure began using animal models in the 1960’s (Eraslan et al, 1966), with the first 21 
attempt at performing the procedure in humans taking place in Saudi Arabia in 2000 (Fageeh et al, 2002). Since then, 22 
over 70 procedures have taken place globally in countries including Turkey, Sweden, China, the USA, the Czech 23 
Republic, Germany, Serbia, Brazil, India, France, and Lebanon and at least 20 births have now been reported 24 
(International Society of Uterus Transplantation, 2020) These numbers are increasing rapidly such that both 25 
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procedures and births doubled between 2016 and 2018,  from 25-52, and 5-10 respectively (Jones et al, 2019: 1311),  26 
and additional  trials are currently being planned in Australia, Belgium, Japan, Sweden, and the UK.  27 
 28 
As the number of cases performed increases so too does the volume of potential data that may be gathered in both 29 
the short and long-term to inform the development, practice, and regulation of UTx. Given the value of such data, 30 
along with the challenges of keeping track of cases and outcomes, especially where data remains unpublished and/or 31 
scattered, scientists and academics conducting research into UTx have increasingly called for the swift creation, 32 
implementation, and management of “an international registry of uterus transplantation cases with follow-up of 33 
patients, children and donors.” (International Society of Uterus Transplantation, 2017)  The establishment of this 34 
registry has now been announced, but it is still in the development stages, with little information currently available 35 
regarding its proposed aims, scope.3 In what follows we – through analysis of the ethical, scientific and legal literature 36 
surrounding medical registries and work undertaken by the International Society for Uterus Transplantation (ISUTx) 37 
– explore: the potential benefits for both physicians, patients, and wider stakeholders that may be provided by the 38 
creation of an International Registry for Uterus Transplantation (IRUTx); how to determine the kinds of information 39 
that should be collected and collated; and a number of ethical and legal challenges that the development of an 40 
international registry for UTx may pose in terms of consent, privacy, researcher compliance, and governance.  41 
 42 
2. Designing the International Registry for Uterus Transplantation: Aims and Scope 43 
 44 
In late 2017, during the ‘1st Congress of International Society for Uterus Transplantation (ISUTx)’, the then ISUTx 45 
President and leader of the Swedish uterus transplantation team, Professor Mats Brännström, together with Dr. César 46 
Díaz García, presented the Society’s proposal to design and manage an international registry of uterus transplantation 47 
cases. (International Society of Uterus Transplantation, 2017) They set forth the first detailed plans available for the 48 
design and development of what they described as a “Patient-based, user-friendly, centralized, secure, anonymous, 49 
exhaustive and specific” registry of UTx cases. (Brännström et al, 2017) Their stated aims for the registry were to 50 
provide “a strong body of knowledge” with “validated data on: efficacy, safety [and] other outcomes” (Brännström, 51 
et al, 2017)  for donors, recipients and children born through UTx. An update on the Society’s progress and a first 52 
look at an extensive draft version of the registry was provided a year later at the ‘1st State of the Art Meeting of ISUTx’ 53 
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(International Society of Uterus Transplantation, 2018) The Society’s intentions for the registry were then confirmed 54 
in a 2019 paper which stated: 55 
 56 
A global UTx registry, containing data in relation to donor, recipient, surgery, immunosuppression, and 57 
pregnancy, has been created by ISUTx. Future annual reports and registry-based research studies will provide 58 
results on activity and scientific results within this emerging field of infertility treatment, with major elements 59 
of both reproductive surgery and assisted reproduction.  (Brännström et al, 2019:9)  60 
 61 
The launch of the registry was then confirmed in a newsletter distributed to the members of ISUTx from the Society 62 
in January 2020. However, as has been confirmed by private communication with the President and past President of 63 
the Society, the registry is, at the time of writing this paper (April 2020) still under construction and there is very little 64 
publicly available information regarding its planned aims and scope. We argue that it is vital for ISUTx to establish 65 
the purpose of the registry from the outset as it is only once the purpose and goals of the registry are determined that 66 
the data required to achieve these goals can be identified (PARENT Cross border Patient Registries iNiTiative. 67 
2015:6.3)From the little information that is available it can be noted that the proposed scope of the registry seems 68 
rather broad with plans to utilize the information of which it is comprised for research, educational, and oversight 69 
purposes by or for the benefit of) a number of different possible stakeholder groups, such as donors, recipients, future 70 
beneficiaries of UTx research, women with AUFI, children created through UTx, physicians/teams 71 
conducting/planning to conduct UTx trials, psychologists, regulators, funders, journalists, and academics. A broad 72 
scope is not necessarily disadvantageous. For, clearly defined and well managed registries serving multiple purposes 73 
are able to provide greater benefits for stakeholders than those with a more limited remit.  In the context of the IRUTx 74 
these benefits are likely to include (but may not be limited to):  75 
 76 
• Increases in data reliability through reduction of challenges for patient safety, and research and development, 77 
associated with reporting biases such as publication and time lag bias; and the use of different measurement 78 
tools for the same/similar outcomes through standardization of data reported;  79 
• The production (and encouragement) of more and better-informed comparative research due to access to 80 
higher quality, centralized, and standardized data on existing cases as well as published literature; 81 
• Greater awareness of AUFI and UTx among members of the public and journalists through information 82 
disseminated on the registry website, and newsletters.  83 
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• Greater levels of understanding of AUFI and UTx among stakeholders lacking access to the academic 84 
literature or unpublished data such as journalists and members of the public resulting from the availability 85 
of up to date, verified, and centrally located information (in the form of annual reports of key outcomes).  86 
• Higher quality patient consent due to ability of individual research teams to more accurately inform patients 87 
about current state of knowledge of risks and benefits of UTx;   88 
• Better patient safeguarding through faster identification of technique variations/patient 89 
groups/teams/individual physicians etc. demonstrating poor patient outcomes; and/or 90 
• Reductions in duration of the surgical learning curve for teams preparing to trial the procedure and 91 
subsequent reductions in patient risks associated with this.4 92 
 93 
To achieve such a wide range of benefits, however, the data collected and collated in the IRUTx must be sufficiently 94 
complete, accurate, and relevant to the interests of the stakeholders it serves, and wholly compliant with national and 95 
international guidelines regarding data protection and privacy. It is therefore imperative, in order to ensure that the 96 
time, effort, resources, and information funnelled into establishing and operating the registry are not wasted, that the 97 
IRUTx is carefully designed to maximise the chances that it will embody these four characteristics. Completeness and 98 
accuracy will, of course, primarily be achieved through the management, funding, and population of the registry once 99 
launched. Steps, however, can be taken at the design stage of the registry to increase their likelihood such as through 100 
a clear management structure; the creation of viable funding strategies; and ensuring easy access, an intuitive end user-101 
interface for those depositing data in the registry. 102 
 103 
Ensuring relevance for stakeholders and/or deciding which potential stakeholders the registry should cater for, 104 
however, requires significant effort at the design stage as it can be noted that once the registry is up and running it 105 
may prove difficult, costly, and time consuming to add and complete datasets later stage. The initial process of selecting 106 
and building data sets may determine the final success of the IRUTx and is one of the most important and challenging 107 
tasks of a new registry (Zaletel et al, 2015:s. 6.3). For, in determining the datasets to include in the IRUTx those 108 
designing it must seriously consider a number of practical and ethical considerations regarding: the diverse priorities 109 
and interests of different stakeholder groups, and their views regarding the relative importance of including different 110 
datasets; the weightiness of the interests and preferences of different stakeholders regarding the inclusion/exclusion 111 
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of different datasets; and, the level of priority (if any) to accord to the interests of those who contribute to the registry 112 
or are most burdened by its creation such as patients (who provide their data), UTx teams (who record their cases), 113 
and those who fund the registry. 114 
 115 
Those designing the IRUTx will therefore be forced to acknowledge and explore how different prospective registry 116 
designs could serve to advance or set back the interests of different stakeholder groups, and engage the key ethical 117 
principles often raised by research involving human volunteers: respect for persons, beneficence/non-maleficence, 118 
and justice (National Commission for the Protection of Human Subjects of Biomedical and Behavioural Research, 119 
1978). A key question in such discussions will likely be how to balance the privacy and welfare interests of those whose 120 
personal information is included in the registry (donors, recipients and children) against the welfare interests of future 121 
beneficiaries of UTx research, and the interests of researchers and funders. For, while a concern for the interests of 122 
the former group generally motivates consideration of necessity and the limitation of datasets included in the registry 123 
a concern to maximise benefits for the latter tends to push in the opposite direction. How to balance such 124 
considerations and settle on a registry design that is acceptable to all stakeholders has been the subject of some 125 
discussion in the literature surrounding clinical trials where initiatives like SONG (standardized outcomes in 126 
Nephrology), OMERACT (outcome measures in Rheumatology)and COMET (Core Outcome Measures in 127 
Effectiveness Trials) have proposed a number of methods for establishing core datasets for clinical trials (SONG 128 
Initiative, 2017; Boers er al, 2014; Williamson et al, 2017) These may prove useful in the design of the IRUTx and 129 
have included: systematic literature reviews; the use of focus groups; stakeholder interviews; Delphi Surveys; and 130 
Consensus Workshops (SONG Initiative, 2017:7)  131 
 132 
3. Governance and Oversight 133 
 134 
In order to foster professional and public confidence in the IRUTx - which should, in turn, encourage participation 135 
from patients, and physicians conducting research into UTx - significant care should be taken to ensure transparent 136 
and egalitarian governance and oversight of the registry and its activities. These should be codified, reflect the nature 137 
and extent of the registry’s operations from the outset, be suitably representative of different key stakeholder groups, 138 
and ensure effective registry operation and longevity. The early establishment of a governance plan will assist in the 139 
design and maintenance of the IRUTx (Zaletel et al, 2015:s6.1). Given the small size of the registry it is likely that the 140 
majority of IRUTx governance and oversight activities – such as those regarding day-to-day finances and 141 
administration, funding, liaison with stakeholders, registry maintenance, quality assurance and data-cleaning 142 
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procedures, registry reports, and data access, use and publication (Gliklich et al, 2014:2.5) will  be undertaken and 143 
determined by the registry’s executive/steering committee.  144 
 145 
The executive/steering committee should be comprised of members of various different stakeholder groups to ensure 146 
that the perspectives of all with the greatest stake in the registry’s interests and perspectives are taken into account. 147 
Given the many and complex jobs of the executive/steering committee it is also imperative that it consult with relevant 148 
experts from finance, ethics, law and biostatistics when required to ensure best practice and compliance with national 149 
and international legislation. In order to increase accountability to the wider stakeholders the IRUTx serves and to 150 
allow the committee’s members to benefit from the advice of a wider community of experts and stakeholders it is also 151 
advisable that an Independent Advisory Board (or equivalent) is formed (Gliklich et al, 2014:4.2). With all the 152 
operations of the IRUTx, transparency, openness and visibility is key; from the members and role of the 153 
executive/steering committee, the policies, and consent processes, through to the purposes of data collection, data 154 
protection procedures, and research protocols (amongst others). The creation of a website which includes public 155 
information regarding processes for appointing members, clear objectives, a clear request process for those who seek 156 
to access IRUTx data for their own research work, and details about the funding of the IRUTx will assist in making 157 
the operations of the registry transparent, and correspondingly increase ‘confidence in the scientific integrity and 158 
validity of registry processes, and therefore in the conclusions reached as a result of registry activities.’ (Gliklich et al, 159 
2014:4.1).  160 
 161 
As noted previously, it is also imperative to maximise the benefits that the IRUTx can provide to potential stakeholders 162 
while correspondingly minimizing harms. In service of this aim public information about registry operations could 163 
significantly increase “the scientific utility of registry data by promoting inquiries from scientists with interests to 164 
which registry data may apply.” (Gliklich et al, 2014:4.1) Fair and equitable policies must be formulated and clearly 165 
articulated on the registry’s website and code of practice regarding both the publication of research arising from 166 
registry activities and researcher access to raw registry data. For, while the prospect of data sharing understandably 167 
raises concerns regarding data ownership, consent, privacy, and data protection (explored below), the scientific utility 168 
of the IRUTx will be increased if submission of requests to access registry data from a broad range of disciplines and 169 
researchers is actively encouraged. A significant problem noted by those who manage medical registries in the past 170 
has been that of the underutilization of registry data and the number of research questions which could, but are not, 171 
explored due to limits in terms of  time, expertise and personnel. (Dane et al, 2006) Thus, while those who maintain 172 
or fund the IRUTx may have proprietary interests in first publication/monetization of the registry and may seek to 173 
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embargo data for a certain period of time, such interests should be balanced against the potential benefits that may be 174 
achieved by widening access to registry data as soon as possible.  175 
 176 
Transparent governance and oversight, fair and equitable policies regarding access to data, and clear articulation of 177 
the benefits that this registry could produce should also increase professional confidence in the IRUTx. In turn, this 178 
should encourage physicians to engage with the IRUTx through populating the registry with the necessary data. 179 
Compliance is vital in order to create and maintain a sufficiently complete and accurate registry and avoid the 180 
introduction of resulting bias. However, as the IRUTx will not be established by primary national or international 181 
legislation there is no legal basis though which compliance can be compelled. Ethical question marks also arise if 182 
actively coercive or manipulative activities are undertaken to increase compliance from physicians such as through 183 
denial of requests to access data for research purposes or expulsion from the ISUTx. Such activities could, after-all, 184 
have serious and negative effects on patient welfare, safety, and consent to inclusion in the registry. Given the 185 
association of the IRUTx with the ISUTx, however, the Society’s soft power could be harnessed to encourage 186 
compliance from society members through reminders in newsletters, promotion at the annual ISUTx conference, etc. 187 
 188 
Careful consideration of how to ensure stable, appropriate, and sustainable funding sources and strategies is also 189 
crucial at this initial planning stage. With a desire for long-term follow-up studies of children born from a donated 190 
uterus, as well as recipients and donors, the continuing financial stability of the IRUTx along with the maintenance of 191 
the datasets that it will hold is of significant concern. The costs associated with populating, maintaining and managing 192 
the registry over the long term should not be underestimated and there is a pressing need to maximise funding and 193 
identify sustainable funding sources able to provide long-term support to ensure the IRUTx is able to meet its goals. 194 
Finally, it is imperative that IRUTx funders and the conditions attached to their support are disclosed and visible to 195 
all stakeholders and that sources of funding are carefully vetted by the registry’s executive/steering committee. The 196 
presence of ethical concerns regarding funder activities or worries about conflicts of interest and/or inappropriate 197 
levels of influence over registry activities may, after-all, impact levels of confidence in outputs produced from registry 198 
data and ultimately threaten the long-term viability of the IRUTx. This is especially pressing where funding is obtained 199 
from non-governmental sources such as patient groups, private companies and foundations who may have a vested 200 
interest in UTx.  201 
 202 
4. Consent, Privacy and Data Protection 203 
 204 
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In order to ensure public confidence in the IRUTx, it is important that the IRUTx is a transparent body that upholds 205 
ethical principles. Openness as to what information is deposited with it, who can access that information, and how it 206 
will be used must be a central principle of the IRUTx.  207 
 208 
The IRUTx may have several roles to fulfil, and these, as noted previously, are likely to include reporting and research. 209 
However, the IRUTx could also expand to encompass broader informational, educational and advisory roles which, 210 
as noted previously, may significantly increase the prospective benefits provided by the registry. An informational role 211 
would require the IRUTx to be public as well as private facing, providing annual updates to the public that may include 212 
information such as the number of uterus transplants performed worldwide, pregnancies, and births recorded. The 213 
IRUTx could also provide up-to-date public facing information about the techniques utilised in UTx, the risks for 214 
donors and recipients, and the alternatives to UTx. This would be similar to the information provided by the United 215 
Kingdom’s Human Fertilisation and Embryology Authority in the context of fertility treatment more generally 216 
(Human Fertilisation and Embryology Authority, 2017). The IRUTx could also have an educational role and registry 217 
outcomes may be used to update and train physicians and other medical professionals conducting and preparing to 218 
conduct UTx trials, and other stakeholders on specific developments. This may be through annual reports, creation 219 
of educational materials using registry data, and information dissemination on an ad hoc basis to update practice (such 220 
as where registry data disrupts clinical equipoise between different surgical techniques being trialled). Finally, the 221 
IRUTx may also perform an advisory role. As an international registry it could provide updates to governments, policy 222 
makers, regulators, and governing bodies in order to assist with the regulation of uterus transplantation. As such, the 223 
data that the IRUTx will need to be provided with by researchers and practitioners could be extensive. Furthermore, 224 
in order to fulfil these roles, the IRUTx will be dependent upon accurate and timely reporting, which in turn is reliant 225 
upon participant’s initial and ongoing consent to the deposit of data in the IRUTx. 226 
 227 
As noted previously, discussions with stakeholders will help to inform decisions regarding key datasets and to reduce 228 
the collection of unnecessary data. These datasets will be of considerable value; to assist the IRUTx in its public facing, 229 
informational and policy role, and importantly to help to inform and educate physicians working in UTx. The role of 230 
consent is central to establishing good working practices of the IRUTx, and to enable it to fulfil its aims. It may, 231 
therefore, be argued that there is a need for a single reporting process which would encompass both a notification 232 
procedure, and a more detailed dataset. The notification procedure may be compared to any other medical treatment 233 
that mandates compulsory reporting, such as termination of pregnancies in England and Wales. For example, 234 
physicians would report that a transplant has taken place, the type of donor, and the outcome of that transplant. It 235 
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would be strongly encouraged that all physicians working in UTx comply with this notification procedure, thereby 236 
assisting in the accurate compilation of procedures and outcomes. A more detailed dataset would assist the IRUTx in 237 
its educational role, as well as providing information for more detailed statistical reporting. However, not all 238 
participants in a UTx trial may be willing for detailed personal data to be transferred to the IRUTx and an autonomous 239 
decision not to consent to the inclusion of their datasets should be respected. The compilation of large datasets is, 240 
after-all, not without its risks, and some participants may be understandably reluctant to transfer personal data to a 241 
central Registry. 242 
 243 
The major risk of depositing detailed data within a central Registry is that the donors and recipients may be easily 244 
identifiable, even when data is anonymised. This concern is especially compelling in the context of uterus 245 
transplantation given the relatively small pool of potential recipients and media interest in the procedure. For example, 246 
previous recipients have been identified in the media either in press releases from centres that have performed UTx, 247 
or in interviews post-birth (BBC News, 2020). Information disclosed could then be matched with the anonymised 248 
data in the Registry. This risk of identification will reduce with time and corresponding increases in recipient numbers. 249 
However, the risk of privacy breaches must not be underestimated, and UTx recipients should be informed of such 250 
risks prior to consenting to the deposit of their data within the registry to ensure that they are in receipt of sufficient 251 
information to make an informed choice regarding participation. 252 
 253 
The IRUTx will therefore need to establish procedures to ensure that appropriate consent of participants has been 254 
obtained prior to their data being deposited with the IRUTx. It is important that physicians worldwide review the 255 
consent forms signed by recipients and donors prior to the establishment of the IRUTx, to ensure that the transferral 256 
of data to a central international registry is within the scope of the consent given. It is also vital that participants in 257 
UTx have the opportunity to withdraw consent to data sharing. It must not be presumed that broad consent to 258 
participate in research will also cover the transference of data to an international registry. An interactive consent model 259 
that allows participants to vary their consent preferences would allow participants greater control over their personal 260 
data (Holm et al, 2019). Moving forward, it is recommended that the IRUTx establish a standardised consent form 261 
for participants with regard to the sharing of their data with the IRUTx, and the purposes for which that data is being 262 
stored, as well as establishing an interactive consent model. Participant’s consent to involvement in long-term follow 263 
up studies must also be considered; an interactive consent model could encourage participation in long-term studies 264 
as participants may feel in control of their data. Researchers desire access to data held by the IRUTx in order to 265 
determine the long-term well-being of donors, recipients, and any children born as a result of UTx. Follow up studies 266 
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on participants of UTx are also to be encouraged. For only longitudinal studies will establish the long-term safety of 267 
the procedure and the health and wellbeing of recipients, donors, and children born.5  268 
 269 
As noted previously, unlike bodies established through primary legislation, such as the United Kingdom’s Human 270 
Fertilisation and Embryology Authority (Human Fertilisation and Embryology Act 1990), the IRUTx will only have 271 
persuasive powers to encourage physicians to deposit the required data into the Registry on a regular basis. The IRUTx 272 
will play a vital role in stressing the importance to researchers of establishing core datasets, and that submissions 273 
should include core data in order to assist with this process. If data collection and deposit are seen to be arduous and 274 
time-consuming tasks, they are less likely to be completed, so ease of access is significant. The applicable governing 275 
law must be considered and communicated to physicians and participants in UTx; this is important for both the 276 
IRUTx and those who deposit data within it. Privacy concerns have increased in recent years, and it is therefore 277 
essential that the IRUTx sufficiently respects and upholds the privacy of those whose data is submitted to and included 278 
in the registry, as well as ensuring that anyone who submits and/or is able to access the data complies with the relevant 279 
law. Sanctions for those who breach the relevant law must also be clear, and enforceable. Similar bodies in other 280 
contexts, such as the UK’s Stem Cell Bank, have been criticised on these grounds (Hammond-Browning et al, 2013). 281 
The European Union’s (EU) General Data Protection Regulation (Regulation (EU) No 2016/679) is the strictest set 282 
of data protection regulations worldwide and could provide a robust benchmark for the Registry.  A key aim of the 283 
GDPR is to make data protection ‘by design and by default’ throughout its lifecycle (Information Comissioner’s 284 
Office, 2019:197-205). It provides legal safeguards for personal data within the EEA and the UK6 regardless of where 285 
the processing of the data takes place. The GDPR will already apply to public and private institutions performing UTx 286 
within the EEA and UK. Significantly,  GDPR restricts the transfer of personal data outside the EEA (even for 287 
processing) unless the country in question can demonstrate that the rights of individuals are adequately protected 288 
(General Data Protection Regulation, Art. 45; Information Commissioner’s Office, 2019:  260-277). Practical guidance 289 
on compliance with the GDPR, where personal data is transferred and disclosed between organisations, can be found 290 
in the Code of Practice produced by the UK’s designated enforcement body, the Information Commissioner’s Office.  291 
 292 
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It states: 293 
The most important thing is to ensure that the organisations involved in data sharing work together to ensure 294 
that the individuals concerned know who has, or will have, their data and what it is being used for, or will be 295 
used for. The primary responsibility for doing this falls to the organisation that collected the data initially. 296 
However, it is good practice for all the organisations involved to ensure that, throughout the data sharing 297 
process, individuals remain aware of who has their personal data and what it is being used for. This is 298 
particularly important where the data has been disclosed to another organisation or where it is being used 299 
for a different purpose. (Information Commissioner’s Office, 2012)  300 
 301 
This reinforces the necessity of appropriate consent from participants in UTx before data is deposited with the IRUTx, 302 
and the need for consent before data is shared beyond the IRUTx. As such, accessing data held by the Registry by 303 
parties outside of the EEA requires consideration and planning by the founders of the IRUTx. Enforcement is 304 
decentralised to national level: Member States must establish a supervisory authority that has the competence to 305 
exercise the powers conferred within the GDPR, including complaints and investigations on the application of the 306 
GDPR (Regulation (EU) No 2016/679: Art. 51 & 55). The sanctions that can be imposed for infringements can be  307 
onerous ranging up to €20 million, or 4% revenue whichever is higher (Regulation (EU) No 2016/679: Art. 83). 308 
However, sanctions may be more difficult to impose  where a breach occurs in a non-EEA (or third country).. 309 
Moreover, individuals whose data protection rights are infringed will be able to seek a remedy before the courts 310 
(Regulation (EU) No 2016/679: Art. 79). 311 
 312 
5.  Conclusion 313 
 314 
The value of a registry for UTx is not without doubt. What is apparent is the need for careful design of its aims, 315 
governance, funding, and policies, reasonable strategies to encourage physician compliance and the provision of 316 
relevant training in order to ensure compliance with data privacy laws, and maximise stakeholder benefits. The 317 
initiative taken by the International Society for Uterus Transplantation to set up an international registry is welcomed 318 
and a wide range of benefits may be reaped from the near-future establishment of the IRUTx. A note of caution must, 319 
however, be aired; that the autonomy of participants must be respected, and time is taken to design datasets to ensure 320 
that they are complete, accurate, and relevant to stakeholders, as well as legally compliant. We have argued that there 321 
is a need to establish the goals and purposes of the IRUTx from the outset in order to determine the required datasets 322 
that will ensure its longevity; a need for clear governance and oversight, transparency and openness; clear procedures 323 
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to obtain initial and ongoing consent of participants, with the development of an interactive consent model; and 324 
compliance by all parties with GDPR. 325 
 326 
 327 
Checklist for the establishment of the IRUTx: 328 
 329 
• Establish purpose and goals of the IRUTx from the outset 330 
• Identify key stakeholders and ensure sensitivity to and awareness of their differing priorities and interests, 331 
including conflicts of interests between members of different groups.  332 
• Identify datasets to achieve goals through collaboration with stakeholders  333 
 Stakeholders should be consulted at various stages throughout this process to ensure design 334 
minimises potential harms to and maximises benefits.   335 
 Data must be complete, accurate, relevant, and compliant with national and international 336 
guidelines regarding data protection and privacy 337 
• Identify and establish viable and sustainable funding strategies 338 
• Establish governance plan  339 
 Establish executive committee comprised of different stakeholders that consults with relevant 340 
experts 341 
 Establish Independent Advisory Board 342 
 Establish Code of Practice and IRUTx policies 343 
•  Ensure and maintain transparency in disclosure of funding sources, policies, purposes of research, 344 
members, research protocols 345 
Create website that includes public facing information and contact details for researchers  346 
• Design and establish consent and data protection policies and procedures for data deposit to IRUTx, to 347 
include: 348 
 Review of consent provided to data collection and transfer prior to the establishment of IRUTx 349 
 Establish interactive consent model – allow for withdrawal of consent and encourage 350 
participation in long-term studies. Policies to include information on applicable governing law, 351 
compliance, enforcement and sanctions. GDPR governs transfer of data within and out with the 352 
EU. 353 
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